In Chicago's Northwestern Medicine laboratories, researchers have identified a precise neurological target that offers late-stage Parkinson's patients something that has eluded the field for decades: a way to stop the involuntary movements caused by their medication without sacrificing the medication's benefits.
The problem they're solving is a cruel paradox of modern Parkinson's treatment. The disease, which affects approximately 8.5 million people worldwide, progressively destroys the brain cells that produce dopamine—the chemical messenger that coordinates movement. The standard remedy, a drug called levodopa, converts to dopamine in the brain and works remarkably well. But as Parkinson's progresses and dopamine neurons continue to die, patients need higher and higher doses. Those increased doses trigger a devastating side effect: levodopa-induced dyskinesia, or LID, which causes sudden, uncontrolled movements that can be as disabling as the disease itself.
D. James Surmeier, chair of neuroscience at Northwestern Medicine, and his team set out to understand why this happens. What they discovered, published recently in the journal Neuron, points to a specific malfunction in a small subset of brain cells called indirect pathway spiny projection neurons, or iSPNs. When levodopa doses climb, these cells become flooded with abnormal connections from the cortex—the brain essentially becomes "scrambled," in Surmeier's description. The researchers identified that this scrambling is driven by an upregulation of special NMDA receptors containing a protein called GluN2B.
Rather than trying to lower levodopa doses or manage dyskinesia symptomatically, the team tested a radical idea: what if they could reverse this specific neurological change? Working in a mouse model of levodopa-induced dyskinesia, they used a gene therapy approach to knock down GluN2B expression in iSPNs. The results were striking. Not only did blocking this receptor subunit prevent dyskinesia from developing in the first place—it also reversed dyskinesia that had already taken hold. That reversal happened while the protective benefits of levodopa remained intact.
"What was very exciting was that—in contrast to almost everything else that has been tried in the last 30 years—knocking down this one NMDA receptor subunit in this particular group of cells reversed established dyskinesia," Surmeier said in the study.
The practical pathway forward is particularly promising. The researchers demonstrated that a specially designed viral vector—essentially a molecular delivery system—could achieve the same results as stereotactic brain surgery. This suggests that a future gene therapy for LID might not require the invasive procedures like deep-brain stimulation that currently represent the most effective interventions for severe dyskinesia.
The discovery matters because it reframes the conversation about late-stage Parkinson's. For decades, doctors and patients have accepted dyskinesia as an inevitable trade-off: take the medication that restores movement and lose the ability to control it. This research suggests that trade-off may not be necessary. By targeting one specific neural pathway in one specific cell type, scientists may have found a way to have both symptom relief and movement control.
The work is still in preclinical stages, tested only in mice. But the mechanism is precise, the results are reproducible, and the implications are profound. For the millions of people living with advanced Parkinson's disease, this could mean a new chapter in how their disease is managed.